Current Press Releases
Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
The clinical team at the University of Calgary Cumming School of Medicine is now completing final preparations and training to enable the start of patient recruitment in September. University Health Network and Unity Health Toronto are also working on final ethics and ...
The clinical team at the University of Calgary Cumming School of Medicine is now completing final preparations and training to enable the start of patient recruitment in September. University Health Network and Unity Health Toronto are also working on final ethics and ...
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
- Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)
- Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique off-target effects that block toxin uptake into the kidney tissue
- Arch continues to perform a Phase II trial for LSALT peptide targeting cardiac surgery-associated-AKI
- Drug toxins and CS-AKI account for up to 50% of all AKI occurring in hospitals, for which there is no treatment available
Arch Biopartners Closes Non-Brokered Private Placement
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement disclosed in a press release July 29, 2024 (the “Offering”). Pursuant to the Offering, Arch issued 400,000 common shares priced at $1.50 per common share (the “Common Shares”) for net proceeds of $600,000 CAD. The proceeds of the Offering will be used by Arch as general working capital and certain research expenses that are not covered by the Company’s existing funding ...
